May 13, 2020 / 12:51 PM / 15 days ago

BRIEF-Cardiff Oncology Enters Agreement With Poc Capital To Fund Phase 2 Clinical Trial Of Onvansertib

May 13 (Reuters) - Cardiff Oncology Inc:

* CARDIFF ONCOLOGY ENTERS AGREEMENT WITH POC CAPITAL TO FUND PHASE 2 CLINICAL TRIAL OF ONVANSERTIB IN KRAS-MUTATED METASTATIC COLORECTAL CANCER (MCRC)

* CARDIFF ONCOLOGY - FUNDING WILL ENABLE ADDITION OF NEW TRIAL SITES TO ACCELERATE COMPLETION OF PHASE 2 CLINICAL TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below